KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Total Liabilities: 2009-2024

Historic Total Liabilities for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $1.3 billion.

  • Biomarin Pharmaceutical's Total Liabilities rose 8.37% to $1.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 8.37%. This contributed to the annual value of $1.3 billion for FY2024, which is 29.58% down from last year.
  • According to the latest figures from FY2024, Biomarin Pharmaceutical's Total Liabilities is $1.3 billion, which was down 29.58% from $1.9 billion recorded in FY2023.
  • Biomarin Pharmaceutical's 5-year Total Liabilities high stood at $1.9 billion for FY2023, and its period low was $1.3 billion during FY2024.
  • In the last 3 years, Biomarin Pharmaceutical's Total Liabilities had a median value of $1.8 billion in 2022 and averaged $1.7 billion.
  • Its Total Liabilities has fluctuated over the past 5 years, first increased by 11.12% in 2020, then fell by 29.58% in 2024.
  • Yearly analysis of 5 years shows Biomarin Pharmaceutical's Total Liabilities stood at $1.7 billion in 2020, then dropped by 0.17% to $1.7 billion in 2021, then rose by 1.89% to $1.8 billion in 2022, then rose by 6.67% to $1.9 billion in 2023, then dropped by 29.58% to $1.3 billion in 2024.